Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
469
2015 to 2026
Breakthrough
137
Accelerated
96
Priority review
302
Orphan
469
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2015 | 24 | 8 |
| 2016 | 20 | 2 |
| 2017 | 37 | 8 |
| 2018 | 41 | 12 |
| 2019 | 31 | 6 |
| 2020 | 38 | 10 |
| 2021 | 30 | 8 |
| 2022 | 23 | 11 |
| 2023 | 32 | 12 |
| 2024 | 30 | 14 |
| 2025 | 36 | 8 |
| 2026 | 18 | 10 |
469 approvals
Newest first. Hover a badge for what it means.
- Klygefa (Gefurulimab) · Alexion PharmNov 13, 2026Original approval · BLA 761488NovelOrphan
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
- Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
- Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
- Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
- Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
- Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
To treat Alexander disease in pediatric and adult patients
- Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
To treat erythrocytosis in adults with polycythemia vera
- Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
To treat dermatomyositis in adults
- Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
To treat metastatic pancreatic cancer
- Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
- Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
- Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
To treat narcolepsy type 1
- Zimrixby (Rituximab-Cdxx) · Dr Reddys Labs SAJul 31, 2026
- Jideytro (Zidesamtinib) · NuvalentJul 22, 2026
To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor
- Sarclisa Escena (Isatuximab-Irfc) · Sanofi-Aventis U.S. LLCJul 9, 2026
- Ambelvist (Gadoquatrane) · Bayer HealthcareJun 12, 2026
To detect and visualize lesions with abnormal vascularity, in conjunction with MRI
- Cavhanza (Nilotinib) · CycleMay 29, 2026
- Decnupaz (Pivekimab Sunirine-Pvzy) · Abbvie INCMay 27, 2026
To treat adults with blastic plasmacytoid dendritic cell neoplasm
- Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
- Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Jakafi Xr (Ruxolitinib Phosphate) · Incyte CorpMay 1, 2026
- Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INCMar 26, 2026
- Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Lynavoy (Linerixibat) · InterceptMar 17, 2026
To treat cholestatic pruritus associated with primary biliary cholangitis
- Yuviwel (Navepegritide) · AscendisFeb 27, 2026
To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses
- Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
- Zycubo (Copper Histidinate) · Sentynl Theraps INCJan 12, 2026
To treat Menkes disease
- Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
- Jascayd (Nerandomilast) · Boehringer IngelheimDec 19, 2025
- Myqorzo (Aficamten) · CytokineticsDec 19, 2025
To treat symptomatic obstructive hypertrophic cardiomyopathy
- Daybue Stix (Trofinetide) · Acadia Pharms INCDec 11, 2025
- Orladeyo (Berotralstat Dihydrochloride) · BiocrystDec 11, 2025
- Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy
- Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
To reduce triglycerides in adults with familial chylomicronemia syndrome
- Komzifti (Ziftomenib) · KuraNov 13, 2025
To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options
- Kygevvi (Doxecitine, Doxribtimine) · Ucb INCNov 3, 2025
To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger
- Dehydrated Alcohol (Dehydrated Alcohol) · Be PharmsOct 23, 2025
- Blenrep (Belantamab Mafodotin-Blmf) · Glaxosmithkline LLCOct 23, 2025
- Epioxa Hd/Epioxa Kit (Riboflavin 5'-Phosphate Sodium) · GlaukosOct 17, 2025
- Ferabright (Ferumoxytol) · AzurityOct 16, 2025
- Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
To treat idiopathic pulmonary fibrosis
- Clotic (Clotrimazole) · Carwin Pharm AssocSep 26, 2025
- Palsonify (Paltusotine Hydrochloride) · CrineticsSep 25, 2025
To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option
- Forzinity (Elamipretide Hydrochloride) · Stealth BiotherapsSep 19, 2025
To improve muscle strength in patients with Barth syndrome weighing at least 30 kg
- Koselugo (Selumetinib, Selumetinib Sulfate) · AstrazenecaSep 10, 2025
- Wayrilz (Rilzabrutinib) · Genzyme CorpAug 29, 2025
To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids
- Otezla (Apremilast) · Amgen INCAug 29, 2025
- Dawnzera (Autoinjector) (Donidalorsen Sodium) · Ionis Pharms INCAug 21, 2025
To prevent attacks of hereditary angioedema
- Modeyso (Dordaviprone Hydrochloride) · ChimerixAug 6, 2025
To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.